Research Nester published a report titled “Respiratory Inhaler Device Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers a detailed overview of the global respiratory inhaler devicemarket in terms of market segmentation by product, technology, disease indication, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global respiratory inhaler device market is estimated to garner notable CAGRover the forecast period, i.e., 2022 – 2031. The market is segmented by disease indication into asthma, chronic obstructive pulmonary disease, pulmonary disease, and others. Out of which, the asthma sub-segment is expected to hold the largest share in the global respiratory inhaler device market on account of the consistently rising number of patients with asthma. The data published by the World Health Organization states that asthma affected 262 million people in 2019 and caused 455,000 deaths worldwide.
The global respiratory inhaler device market is expected to grow significantly during the forecast period on the back of rising cases of chronic obstructive pulmonary diseases. Additionally, the growing cases of bronchitis are also a major factor driving the growth of the global respiratory inhaler devicemarket during the forecast period. The data published by the National Center for Biotechnology Information states that 5% of adults in the U.S. suffer from acute bronchitis every year. Apart from this the rising cases of the common cold are also expected to grow the global respiratory inhaler device market during the forecast period. The respiratory inhaler devices are highly effective in providing relief to patients with the common cold.
Regionally, the global respiratory inhaler device market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is estimated to witness modest growth over the forecast period on the back of the presence of well-developed healthcare infrastructure.Furthermore, the Centers for Disease Control and Prevention states that chronic obstructive pulmonary diseases (COPD) affect more than 15 million Americans. On account of this, the global respiratory inhaler device market is projected to witness remarkable growth during the forecast period. The Asia Pacific region is also estimated to witness remarkable growth during the forecast period on account ofthe large number of people suffering from respiratory diseases.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Rising Cases of Common Cold likely to Boost the Market Growth
The data released by American Lung Association states that young children suffer from an average of 6 to 8 colds per year.
The rising cases of the common cold are expected to boost the global respiratory inhaler devicemarket growth during the forecast period. The respiratory inhalers help in relaxing the muscles of the patients and make it easier to breathe, which is the reason the global respiratory inhaler devicemarket is estimated to grow during the forecast period.
However, associated side effects, such as, allergiesare expected to operate as a key restraint to the growth of the global respiratory inhaler devicemarket over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global respiratory inhaler devicemarketwhich includes company profiling ofTeva Pharmaceuticals Industries Ltd, Beximco Pharmaceuticals Ltd., Omron Healthcare Europe B.V, Boehringer Ingelheim International GmbH, Merck & Co., Inc., GlaxoSmithKline plc., Cipla Inc., Koninklijke Philips N.V., PARI GmbH, and AstraZeneca plc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global respiratory inhaler devicemarketthat will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
